Novo Nordisk A/S
Bispecific antibodies
Last updated:
Abstract:
The invention relates to a bispecific antibody comprising a first antigen-binding site capable of binding Factor VII(a) and a second antigen-binding site capable of binding TLT-1, pharmaceutical formulations comprising such bispecific antibodies and uses thereof.
Status:
Grant
Type:
Utility
Filling date:
14 Oct 2021
Issue date:
10 May 2022